CD47 and neoplasm: While most studies have focused on the CD47/signal regulatory protein (SIRP)α interface (the “don’t eat me” signal) [18], the CD47/TSP-1 axis is gaining attention in the field of oncology because it influences tumor cell survival [19] and cancer stem cell differentiation [20], supports chemotherapy and radiotherapy resistance [21], and inhibits the anti-cancer immune response [22–26].